Announcement on Voluntary Disclosure of the Inclusion of the Xeligekimab Injection in the 2025 National Medical Insurance Catalog

About this update from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of the Inclusion of the Xeligekimab Injection in the 2025 National Medical Insurance Catalog The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Chongqing Genrix Biopharmaceutical Co., Ltd. Class A